Page last updated: 2024-10-30

loratadine and Chronic Illness

loratadine has been researched along with Chronic Illness in 56 studies

Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.

Research Excerpts

ExcerptRelevanceReference
"Desloratadine citrate disodium can effectively reduce the severity of chronic urticaria, and its therapeutic mechanism may be related to balancing Th1/Th2 cell function, regulating inflammatory mediators and inhibiting the action of chemokines."9.30Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019)
"Desloratadine citrate disodium treatment effect of chronic urticaria is better, and after treatment, IL4, IL18, IL23, IL33 levels decreased significantly."9.24Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017)
"Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU."9.22Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016)
"Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1."9.14Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009)
"Loratadine added to montelukast has been suggested to improve endpoints of asthma."9.14A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009)
"Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria."9.14The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010)
"To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)."9.13Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008)
"Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)."9.12Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006)
"Once-daily desloratadine 5mg is well tolerated and superior to placebo in reducing pruritus and wheals associated with CIU."9.12Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007)
"The aim of this study is to determine whether montelukast, a LTD4 receptor antagonist, plus desloratadine, is more efficacious than desloratadine alone in the treatment of chronic urticaria."9.11Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004)
"Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive."9.10Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003)
"Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria."9.09Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999)
"To determine whether montelukast plus loratadine provides improved efficacy to montelukast alone in the treatment of chronic asthma."9.09Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000)
"Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study."9.09Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001)
"The H1 antihistamine loratadine reduces cough induced by UNDW."9.08Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough. ( Hirata, K; Kurihara, N; Takeda, T; Tanaka, S; Yoshikawa, J, 1996)
" Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0."8.86Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010)
"To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days."7.88The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018)
"H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria."7.80Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014)
" Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)."7.75Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009)
"The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria."7.68Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992)
" The efficiency and side-effect were evaluated at the end of treatment."6.73Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008)
"Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0."6.72Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006)
"Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity."6.67Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990)
" Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine."6.67Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992)
" Age and sex have no apparent effect on the drug's metabolism and elimination, and food does not affect its bioavailability or absorption."6.44Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007)
"Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist."6.43Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005)
"Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules."6.41Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001)
"H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU)."5.34Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria. ( Chen, W; Chen, X; Li, J; Liu, Z; Peng, C; Su, J; Zhang, W; Zhu, W, 2020)
"Desloratadine citrate disodium can effectively reduce the severity of chronic urticaria, and its therapeutic mechanism may be related to balancing Th1/Th2 cell function, regulating inflammatory mediators and inhibiting the action of chemokines."5.30Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019)
"Desloratadine citrate disodium treatment effect of chronic urticaria is better, and after treatment, IL4, IL18, IL23, IL33 levels decreased significantly."5.24Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017)
"Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU."5.22Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016)
"Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1."5.14Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009)
"Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria."5.14The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010)
"Loratadine added to montelukast has been suggested to improve endpoints of asthma."5.14A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009)
"To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)."5.13Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008)
"Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)."5.12Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006)
"Once-daily desloratadine 5mg is well tolerated and superior to placebo in reducing pruritus and wheals associated with CIU."5.12Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007)
"The aim of this study is to determine whether montelukast, a LTD4 receptor antagonist, plus desloratadine, is more efficacious than desloratadine alone in the treatment of chronic urticaria."5.11Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004)
"Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive."5.10Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003)
"To determine whether montelukast plus loratadine provides improved efficacy to montelukast alone in the treatment of chronic asthma."5.09Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000)
"Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria."5.09Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999)
"Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study."5.09Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001)
"The H1 antihistamine loratadine reduces cough induced by UNDW."5.08Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough. ( Hirata, K; Kurihara, N; Takeda, T; Tanaka, S; Yoshikawa, J, 1996)
" Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0."4.86Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010)
"To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days."3.88The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018)
"H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria."3.80Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014)
" Systemic mastocytosis and other causes of chronic diarrhea, especially therapy with methotrexate, were carefully ruled out."3.77Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis. ( Langner, C; Siegel, C; Thonhofer, R; Trummer, M, 2011)
" Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)."3.75Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009)
"The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria."3.68Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992)
" The efficiency and side-effect were evaluated at the end of treatment."2.73Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008)
"Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0."2.72Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006)
"Loratadine was safe and well tolerated."2.67Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population. ( Cerio, R; Chieira, ML; deGroot, LJ; Giannetti, A; Gonçalves, HM; Guillot, B; Lutsky, BN; Lynde, CW; Schuller, JL; Vareltzides, A, 1993)
" Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine."2.67Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992)
"Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity."2.67Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990)
" Age and sex have no apparent effect on the drug's metabolism and elimination, and food does not affect its bioavailability or absorption."2.44Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007)
"Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist."2.43Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005)
"Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules."2.41Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001)
"Chronic urticaria is a common dermatologic condition that is idiopathic in most cases."2.41Desloratidine for the treatment of chronic urticaria. ( Monroe, EW, 2002)
" Patients could be categorized into four groups based on the results of ASST and SPT to HDM and patients with positive ASST and positive SPT to HDM had the highest disease activity scores, experienced higher frequencies of angioedema, diseases duration, and required higher dosage of loratadine every month, compared with other subgroups (P<0."1.39Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria. ( Chen, W; Hao, F; Song, Z; Zhai, Z; Zhong, H; Zhou, Z, 2013)
"The dermatitis is characterized by redness, hairloss, scaling, pruritus and histologically by epithelial hyperproliferation, infiltration of eosinophils, macrophages and mast cells."1.31Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm). ( Bruijnzeel, PL; Elliott, GR; Gijbels, MJ; HogenEsch, H; van den Hoven, A; Zurcher, C, 2000)

Research

Studies (56)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.79)18.7374
1990's9 (16.07)18.2507
2000's23 (41.07)29.6817
2010's22 (39.29)24.3611
2020's1 (1.79)2.80

Authors

AuthorsStudies
Li, J5
Chen, W5
Peng, C3
Zhu, W4
Liu, Z4
Zhang, W3
Su, J4
Chen, X6
Maouia, A1
Youssef, M1
Leban, N1
Ben Chibani, J1
Helal, AN1
Kassab, A1
Zheng, D1
Yang, X1
Choonhakarn, C1
Chaowattanapanit, S1
Julanon, N1
Yan, J1
Li, Q2
Luo, Y1
Yan, S4
He, Y3
Chen, M3
Zhang, J3
Li, F1
Wang, J1
Zhao, Y2
Yan, X1
Song, Z1
Zhai, Z1
Zhong, H1
Zhou, Z1
Hao, F1
Leiva-Salinas, M1
Francés, L1
Marin-Cabanas, I1
Arribas Granados, MP1
Silvestre, JF1
Başak, PY1
Vural, H1
Kazanoglu, OO1
Erturan, I1
Buyukbayram, HI1
Wen, S1
Guo, A2
Zhang, C1
Zhou, H1
Zeng, W2
Potter, P1
Mitha, E1
Barkai, L1
Mezei, G1
Santamaría, E1
Izquierdo, I1
Maurer, M3
Kennedy, DW1
Raison-Peyron, N1
Reymann, V1
Bessis, D1
Bin, L1
Yi, M1
Leung, DY1
Ciebiada, M1
Ciebiada, MG1
Kmiecik, T1
DuBuske, LM2
Gorski, P1
Potter, PC1
Kapp, A1
Guillet, G1
Jian, AM1
Hauptmann, P1
Finlay, AY1
Grob, JJ3
Auquier, P3
Dreyfus, I3
Ortonne, JP3
Augustin, M1
Ehrle, S1
Lu, S1
Liu, N1
Dass, SB1
Reiss, TF1
Kiyici, S1
Gul, OO1
Baskan, EB1
Hacioglu, S1
Budak, F1
Erturk, E1
Imamoglu, S1
Bachert, C1
Staevska, M1
Popov, TA1
Kralimarkova, T1
Lazarova, C1
Kraeva, S1
Popova, D1
Church, DS1
Dimitrov, V1
Church, MK1
Bérard, F1
Boulinguez, S1
Korkmaz, H1
Eigelshoven, S1
Homey, B1
Hong, JB2
Lee, HC2
Hu, FC1
Chu, CY2
Thonhofer, R1
Siegel, C1
Trummer, M1
Langner, C1
Monroe, EW3
Grattan, CE1
Dawn, G1
Gibbs, S1
Francis, DM1
Monroe, E1
Finn, A1
Patel, P1
Guerrero, R1
Ratner, P1
Bernstein, D1
Nettis, E1
Colanardi, MC1
Paradiso, MT1
Ferrannini, A1
Di Lorenzo, G1
Pacor, ML1
Mansueto, P1
Esposito Pellitteri, M1
Lo Bianco, C1
Ditta, V1
Martinelli, N1
Rini, GB1
Rottem, M1
Elbirt, D1
Sthoeger, Z1
Lachapelle, JM2
Decroix, J1
Henrijean, A1
Roquet-Gravy, PP1
De Swerdt, A1
Boonen, H1
Lecuyer, M1
Suys, E1
Speelman, G1
Vastesaeger, N1
Cassano, N1
Raho, G1
Filieri, M1
D'Argento, V1
Amoruso, A1
Filotico, R1
Vena, GA1
Lam, HC1
Tong, MC1
Van Hasselt, CA1
DuBuske, L1
Khalaf, AT1
Liu, XM1
Sheng, WX1
Tan, JQ1
Abdalla, AN1
Lutsky, BN1
Schuller, JL1
Cerio, R1
Chieira, ML1
Giannetti, A1
Gonçalves, HM1
deGroot, LJ1
Vareltzides, A1
Guillot, B1
Lynde, CW1
Tanaka, S1
Hirata, K1
Kurihara, N1
Yoshikawa, J1
Takeda, T1
Goriachkina, LA1
Peredkova, EV1
Dubertret, L1
Murrieta Aguttes, M1
Tonet, J1
Reicin, A1
White, R1
Weinstein, SF1
Finn, AF1
Nguyen, H1
Peszek, I1
Geissler, L1
Seidenberg, BC1
Gijbels, MJ1
Elliott, GR1
HogenEsch, H1
Zurcher, C1
van den Hoven, A1
Bruijnzeel, PL1
Ring, J2
Hein, R2
Gauger, A2
Bronsky, E1
Miller, B1
Juhlin, L1
Pihl-Lundin, I1
Bernstein, DI2
Fox, RW2
Grabiec, SV1
Honsinger, RW1
Kalivas, JT1
Katz, HI1
Cuss, F1
Danzig, MR1
Garvin, PR1
Abu Shareeah, AM1
Pedersen, MF1
Belaich, S1
Bruttmann, G1
DeGreef, H1
Paul, E1
Pedrali, P1
Tennstedt, D1
Green, AW1
Izuno, GT1
Pleskow, WW1
Willis, I1
Brigante, JR1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® Continuous Treatment Versus Aerius® PRN Regimen on Chronic Idiopathic Urticaria Patient Quality of Life"[NCT00783354]Phase 4129 participants (Actual)Interventional2003-04-01Completed
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020]Phase 2138 participants (Actual)Interventional2015-12-31Completed
Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study[NCT01250652]Phase 424 participants (Actual)Interventional2011-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for loratadine and Chronic Illness

ArticleYear
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
    Clinical drug investigation, 2010, Volume: 30, Issue:2

    Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine

2010
[Diagnostic and physiopathological innovations related to chronic urticaria].
    Annales de dermatologie et de venereologie, 2010, Volume: 137, Issue:5 Suppl 1

    Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoantibodie

2010
Desloratidine for the treatment of chronic urticaria.
    Skin therapy letter, 2002, Volume: 7, Issue:8

    Topics: Chronic Disease; Histamine H1 Antagonists; Humans; Loratadine; Urticaria

2002
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14

    Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl

2005
Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.
    American journal of clinical dermatology, 2007, Volume: 8, Issue:5

    Topics: Acetates; Adolescent; Adult; Child; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Hista

2007
Desloratadine in the treatment of chronic idiopathic urticaria.
    Allergy, 2001, Volume: 56 Suppl 65

    Topics: Cholinergic Antagonists; Chronic Disease; Cytokines; Histamine H1 Antagonists; Humans; Loratadine; S

2001

Trials

32 trials available for loratadine and Chronic Illness

ArticleYear
Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.
    The pharmacogenomics journal, 2020, Volume: 20, Issue:1

    Topics: Adult; China; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Female; Histamine H1

2020
CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients.
    Cutaneous and ocular toxicology, 2017, Volume: 36, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Antioxidants; C-Reactive Protein; Catalase; Chronic Disease; Female

2017
Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:3(Special)

    Topics: Adolescent; Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Interleu

2017
Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:3

    Topics: Administration, Oral; Adult; Biomarkers; Chemokine CCL5; Chemokines; China; Cholinergic Antagonists;

2019
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2016, Volume: 27, Issue:1

    Topics: Age Factors; Child; Child, Preschool; Chronic Disease; Cyproheptadine; Double-Blind Method; Female;

2016
Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.
    Journal of investigational allergology & clinical immunology, 2008, Volume: 18, Issue:5

    Topics: Acetates; Adolescent; Adult; Aged; Cetirizine; Chronic Disease; Cross-Over Studies; Cyclopropanes; D

2008
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
    Allergy, 2009, Volume: 64, Issue:4

    Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu

2009
How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.
    Allergy, 2009, Volume: 64, Issue:4

    Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 Anta

2009
A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:5

    Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Asthma; Beclomethasone; Chronic Disease; Cr

2009
Effect of levothyroxine treatment on clinical symptoms and serum cytokine levels in euthyroid patients with chronic idiopathic urticaria and thyroid autoimmunity.
    Clinical and experimental dermatology, 2010, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Autoimmune Diseases; Chi-Square Distribution; Chronic Disease; Drug Combinations;

2010
The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.
    The Journal of allergy and clinical immunology, 2010, Volume: 125, Issue:3

    Topics: Adult; Aged; Cetirizine; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fem

2010
A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria.
    Journal of the American Academy of Dermatology, 2010, Volume: 63, Issue:5

    Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu

2010
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
    Journal of the American Academy of Dermatology, 2003, Volume: 48, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Child; Chronic Disease; Double-Blind Method; Drug Administr

2003
Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2004, Volume: 34, Issue:9

    Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blin

2004
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:3

    Topics: Acetates; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Hist

2004
[Desloratadine for chronic idiopathic urticaria].
    Harefuah, 2005, Volume: 144, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Hum

2005
Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2006, Volume: 20, Issue:3

    Topics: Administration, Oral; Adult; Belgium; Chronic Disease; Drug Administration Schedule; Female; Histami

2006
Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria.
    International journal of dermatology, 2006, Volume: 45, Issue:4

    Topics: Adult; Aged; Biomarkers; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lo

2006
Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
    American journal of clinical dermatology, 2007, Volume: 8, Issue:1

    Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine H1

2007
Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine.
    The Journal of laryngology and otology, 2007, Volume: 121, Issue:12

    Topics: Adult; Chronic Disease; Endoscopy; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadin

2007
Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Dipyridamol

2008
Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:1

    Topics: Activities of Daily Living; Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M

2008
Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population.
    Arzneimittel-Forschung, 1993, Volume: 43, Issue:11

    Topics: Child; Chronic Disease; Dermatitis, Contact; Humans; Loratadine; Skin; Solutions; Suspensions; Terfe

1993
Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough.
    Thorax, 1996, Volume: 51, Issue:8

    Topics: Adult; Chronic Disease; Cough; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagon

1996
[The clinical efficacy of Claritin in treating allergic diseases].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Child; Chronic Disease; Histamine H1 Antagon

1997
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 1999, Volume: 12, Issue:1

    Topics: Adult; Analysis of Variance; Appendicitis; Benzimidazoles; Chronic Disease; Double-Blind Method; Ele

1999
Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
    Archives of internal medicine, 2000, Sep-11, Volume: 160, Issue:16

    Topics: Acetates; Adolescent; Adult; Aged; Asthma; Chronic Disease; Cross-Over Studies; Cyclopropanes; Doubl

2000
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
    International journal of dermatology, 2001, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aged; Cholinergic Antagonists; Chronic Disease; Dizziness; Double-Blind Method; D

2001
Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.
    Arzneimittel-Forschung, 1992, Volume: 42, Issue:9

    Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Hydroxyzine; Loratadine; Midd

1992
Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
    International journal of dermatology, 1992, Volume: 31, Issue:5

    Topics: Adult; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Loratadine; Male; Pru

1992
Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
    Annals of allergy, 1990, Volume: 64, Issue:2 Pt 2

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Clinical Trials as Topic; Cyprohepta

1990
Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria.
    Journal of the American Academy of Dermatology, 1988, Volume: 19, Issue:1 Pt 1

    Topics: Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Histamine H1 Antagon

1988

Other Studies

18 other studies available for loratadine and Chronic Illness

ArticleYear
The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.
    International journal of dermatology, 2018, Volume: 57, Issue:4

    Topics: Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Maintena

2018
[Association of CACNA1C gene genetic polymorphism with the susceptibility as well as prognosis for chronic spontaneous urticaria].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2018, Sep-28, Volume: 43, Issue:9

    Topics: Calcium Channels, L-Type; Chronic Disease; Genetic Predisposition to Disease; Histamine H1 Antagonis

2018
C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level.
    Experimental dermatology, 2019, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Aged; Animals; Benzimidazoles; C-Reactive Protein; China; Chronic Disease; Chroni

2019
Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anti-Allergic Agents; China; Chronic Disease; Female;

2013
Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:5

    Topics: Anti-Allergic Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hist

2015
Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria.
    International journal of dermatology, 2014, Volume: 53, Issue:12

    Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Cetirizine; Chronic Disease; Female; Histamine H

2014
Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.
    Journal of dermatological science, 2014, Volume: 76, Issue:3

    Topics: Adolescent; Adult; Aged; Asian People; Benzimidazoles; Case-Control Studies; China; Chronic Disease;

2014
EDITORIAL.
    International forum of allergy & rhinology, 2015, Volume: 5, Issue:12

    Topics: Animals; Carcinogenesis; Chronic Disease; Diagnosis, Differential; Histamine Antagonists; Humans; Lo

2015
Follicular Traction Urticaria: A New Form of Chronic Inducible Urticaria?
    Acta dermato-venereologica, 2017, 04-06, Volume: 97, Issue:4

    Topics: Administration, Oral; Biopsy; Chronic Disease; Drug Administration Schedule; Female; Hair Follicle;

2017
Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine.
    The Journal of allergy and clinical immunology, 2017, Volume: 139, Issue:4

    Topics: Adult; Chronic Disease; Female; Genetic Association Studies; Genetic Predisposition to Disease; Geno

2017
Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:3

    Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chr

2009
[Omalizumab for therapy-resistant chronic urticaria with angioedema].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:10

    Topics: Adult; Angioedema; Anti-Allergic Agents; Anti-Inflammatory Agents; Antibodies, Anti-Idiotypic; Antib

2010
Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2011, Volume: 110, Issue:3

    Topics: Adolescent; Adult; Cetirizine; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Loratadine

2011
Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis.
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:9-10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Biopsy; Chronic D

2011
Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2003, Volume: 33, Issue:3

    Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Basophils; Case-Control Studies; Chronic Dise

2003
Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm).
    Experimental dermatology, 2000, Volume: 9, Issue:5

    Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Calcitriol

2000
Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects.
    Acta dermato-venereologica, 1992, Volume: 72, Issue:3

    Topics: Adult; Aged; Chlorpheniramine; Chronic Disease; Eosinophils; Female; Histamine; Histamine H1 Antagon

1992
Computed phonetograms in adult patients with benign voice disorders before and after treatment with a nonsedating antihistamine (loratadine).
    Folia phoniatrica, 1991, Volume: 43, Issue:2

    Topics: Adult; Aged; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Laryngitis; Lor

1991